These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Tamura Y; Hamajima K; Matsui K; Yanoma S; Narita M; Tajima N; Xin KQ; Klinman D; Okuda K Neurobiol Dis; 2005 Nov; 20(2):541-9. PubMed ID: 15908227 [TBL] [Abstract][Full Text] [Related]
27. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. DeMattos RB; Bales KR; Cummins DJ; Dodart JC; Paul SM; Holtzman DM Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8850-5. PubMed ID: 11438712 [TBL] [Abstract][Full Text] [Related]
28. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. DeMattos RB; Bales KR; Cummins DJ; Paul SM; Holtzman DM Science; 2002 Mar; 295(5563):2264-7. PubMed ID: 11910111 [TBL] [Abstract][Full Text] [Related]
29. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708 [TBL] [Abstract][Full Text] [Related]
30. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. van Groen T; Kiliaan AJ; Kadish I Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076 [TBL] [Abstract][Full Text] [Related]
31. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920 [TBL] [Abstract][Full Text] [Related]
32. Quantitative and mechanistic studies of Abeta immunotherapy. Golde TE; Das P; Levites Y CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):31-49. PubMed ID: 19275635 [TBL] [Abstract][Full Text] [Related]
33. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. Yamada K; Yabuki C; Seubert P; Schenk D; Hori Y; Ohtsuki S; Terasaki T; Hashimoto T; Iwatsubo T J Neurosci; 2009 Sep; 29(36):11393-8. PubMed ID: 19741145 [TBL] [Abstract][Full Text] [Related]
34. Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model. Yang J; Pattanayak A; Song M; Kou J; Taguchi H; Paul S; Ponnazhagan S; Lalonde R; Fukuchi K J Mol Neurosci; 2013 Feb; 49(2):277-88. PubMed ID: 22945846 [TBL] [Abstract][Full Text] [Related]